New Delhi, Medicare News, May 15, 2016
In a $293 million cash deal India’s Sun Pharmaceutical Industries Ltd. has agreed to buy 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, the Indian company said.
In a statement issued late Tuesday, the company said a wholly owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293 million.
“These brands have combined annualised revenues of approximately $160 million and address medical conditions across several therapeutic areas,” the company said.
“Under the terms of the agreements, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorisations to Sun Pharma’s subsidiary.”
The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The partner will also be responsible for distribution of the brands.
“Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future,” Dilip Shanghvi, managing director, Sun Pharma was quoted as saying in the statement.
As per the December-2015 IMS Data, the size of the Japanese pharmaceutical market was estimated at $73 billion, accounting for over seven percent of the $1 trillion global pharmaceutical market.
Govt supports indigenous manufacturing of complex pharma excipients by Nitika Pharmaceutical Specialties
For commercial-scale production of 14 complex excipients The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India has extended financial support to Nitika Pharmaceutical Specialties Private…
